Investigational drug · Phase 2
CVXGA
Also called: CVXGA50, PIV5-SARS CoV-2
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "CVXGA"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CVXGA", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "CVXGA" as an intervention, largest first.
- A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsPivotal-lookingCompleted
CyanVac LLCIndustry
NCT06742281 · 432 participants · Start Dec 5, 2024 · Primary completion Jun 15, 2026
Drug: CVXGA (CVXGA50); COMIRNATY® · For: COVID-19
Sites: Anniston, Alabama; Phoenix, Arizona; Chula Vista, California · 55 sites in all
- A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy AdultsPivotal-lookingCompleted
CyanVac LLCIndustry
NCT05736835 · 227 participants · Start Sep 21, 2023 · Primary completion Dec 16, 2025
Drug: CVXGA · For: COVID-19
Sites: San Diego, California; Boise, Idaho; Sioux City, Iowa · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters.
Briggs K, Gingerich MC, Gingerich A, et al. · Vaccine 2026
Also in development for COVID-19
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
- DAS181Phase 31 trial
Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised
- SCTA01Phase 31 trial
Sinocelltech Ltd. · COVID-19, SARS-CoV-2
- VYD222pemivibartPhase 31 trial
Invivyd, Inc. · COVID-19, SARS-CoV-2
- VYD2311-MDPhase 31 trial
Invivyd, Inc. · COVID-19
- VYD2311-SDPhase 31 trial
Invivyd, Inc. · COVID-19
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.